Skip to main content
. 2015 May 12;100(7):2743–2750. doi: 10.1210/jc.2015-1158

Figure 1.

Figure 1.

Expected diagnostic performance of the MPT in thyroid nodules with AUS/FLUS or FN/SFN cytopathology according to thyroid cancer prevalence in a given test population. The graphs show the PPV (A), NPV (B), rate of true benign molecular calls (C), and rate of potentially avoidable surgeries (D) calculated using the sensitivity and specificity obtained in the present study and pretest probabilities of cancer ranging from 0–100%. D, the rate of potentially avoidable surgeries when no molecular testing is performed (no test, dashed line) is the proportion of benign cases by histopathology after diagnostic surgery, ie, [1-prevalence].